Retina Institute of Hawaii   Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Honolulu HI United States (2001)

Organization Overview

First Clinical Trial
2008
NCT00804934
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

ico-007 (1 trial)

ranibizumab (lucentis) (2 trials)

Drugs in Phase 1 Trials (1)

pegaptanib (macugen) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Retinopathy (Phase 1)

Edema (Phase 2)

Macular Edema (Phase 2)

Retinal Detachment (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 3